Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
Coya Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/21/2023 |
4
| Weinand Dieter (Director) has filed a Form 4 on Coya Therapeutics, Inc.
Txns:
| Granted 10,000 options to buy
@ $3.43, valued at
$34.3k
|
|
08/21/2023 |
3
| Weinand Dieter (Director) has filed a Form 3 on Coya Therapeutics, Inc. |
08/21/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
07/14/2023 |
8-K
| Quarterly results |
07/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
06/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/23/2023 |
8-K
| Other Events Interactive Data |
05/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
05/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/16/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
05/12/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
05/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/10/2023 |
8-K
| Quarterly results |
05/08/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
04/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/29/2023 |
8-K
| Quarterly results |
03/22/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
03/21/2023 |
8-K
| Investor presentation |
03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
03/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/01/2023 |
4
| Berman Howard (CEO) has filed a Form 4 on Coya Therapeutics, Inc.
Txns:
| Granted 165,000 options to buy
@ $3.85, valued at
$635.3k
|
|
03/01/2023 |
4
| Hepner Adrian (Chief Medical Officer) has filed a Form 4 on Coya Therapeutics, Inc.
Txns:
| Granted 115,000 options to buy
@ $3.85, valued at
$442.8k
|
|
03/01/2023 |
4
| SNYDER DAVID S (CFO) has filed a Form 4 on Coya Therapeutics, Inc.
Txns:
| Granted 115,000 options to buy
@ $3.85, valued at
$442.8k
|
|
02/14/2023 |
SC 13G
| Berman Howard reports a 14.2% stake in COYA THERAPEUTICS, INC. |
01/25/2023 |
8-K
| Other Events Interactive Data |
|
|
|